A top manager at Gilead Sciences told the SEC about a plan to sell $436K of Gilead Sciences shares around Sep 15, 2026. The shares did not come from pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 144 — Notice of Proposed Sale of Securities

All the details

Dates, kept separate

Planned sale date: Sep 15, 2026
Reporting period: Not applicable
Notice filed with the SEC: Sep 15, 2026

OfficerPlanned saleNot from pay

Context

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001950047-26-009467
Filed / recorded: Sep 15, 2026, 8:04 PM UTC

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Added to OQRO

Oct 2, 2026, 11:01 AM UTC

Parser

form144-v1

Data quality

Read from the record; company matched by name

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Table

Non-derivative (Table I)

Transaction date

—

Shares / units

—

Price per share

—

Shares owned after

—

Ownership form

Direct

Amendment

Around the same time

CEO sold ~$1.77M of Gilead Sciences

Scheduled in advance3d ago

CEO sold ~$446K of Gilead Sciences

Scheduled in advance3d ago

13d ago

2,223Shares

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record